All News
Subcutaneous Biosimilars? (10.27.2023)
Dr. Jack Cush reviews RheumNow's top entries the PMR Campaign, news, journal reports and regulatory actions.
Read Article
Anti-Phospholipid Antibodies - Infrequent in Certain Groups
d
MedPage Today
Among patients with systemic lupus erythematosus (SLE), high titers of anti-phospholipid (aPL) antibodies were most prevalent in whites and Latinos and less so for Black and Asian individuals, researchers found.
Read Article
TNR - Controversies in PMR
A TNR Panel discussion on controversies in PMR: diagnosis, imaging, PCP roles, Lumping vs. Splitting.
Featuring Drs. Sarah Mackie, Wolfgang Schmidt, and Len Calabrese.
Moderated by Dr. David Liew.
Recorded on 10/24/2023
Read Article
ACR 2022 Guideline on Glucocorticoid-Induced Osteoporosis
The ACR has published its updated recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP) for patients receiving >3 months treatment with glucocorticoids (GCs) ≥2.5 mg daily.
Read Article
#PMR Mythbusters: PMR is Only Proximal
https://t.co/tRed7Zsaxi https://t.co/PWP5boH6NA
Dr. John Cush RheumNow ( View Tweet)
ACR 2022 Guideline on Glucocorticoid-Induced Osteoporosis
The ACR has published its updated recommendations for prevention and treatment of GIOP for patients receiving >3 months treatment with glucocorticoids (GCs) ≥2.5 mg daily.
https://t.co/oKVovOafl7 https://t.co/irxsAxMwKA
Dr. John Cush RheumNow ( View Tweet)
#PMR and Telemedicine: do we really need an office visit?
Can we use a synchronous audiovisual visit or a rheumatology eConsult to evaluate the patient's symptoms quickly? Does it allow us to make an accurate diagnosis?
https://t.co/JTAYstzDk8 https://t.co/NNvYfdkm2K
Dr. John Cush RheumNow ( View Tweet)
CMAJ analysis of 28 studies & 24 million pts Rx opioids suggest a higher risk of opioid overdose w/: high-dose opioids, fentanyl, multiple opioid Rxs, overdose Hx, Dx of substance use, depression, bipolar, mental illness, pancreatitis https://t.co/FprgoaTvXR https://t.co/G0QjNJTezu
Dr. John Cush RheumNow ( View Tweet)
#PMR Polymyalgia rheumatica is very common, yet there is little research on the Dx & Management of PMR by #PCPs! Mayo study prevalence 701 per 100,000 (women=870 and men =508 per 100,000 population). https://t.co/7JZFeRPRnn https://t.co/0JoaXL4qv0
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023.
https://t.co/Wdk4tvnlRz https://t.co/YFdvfbyrpJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Unpopular opinion: spinach can be bad for you
The title might have misled you; simply, Dr Stephen Paget’s analogy comparing the drastic response to steroids in #PMR to Popeye’s spinach stuck with me!
https://t.co/VNlY6O5YeE https://t.co/RZmbVL2EiZ
Dr. John Cush RheumNow ( View Tweet)
Methotrexate in OA
Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more.
https://t.co/RHiRBxajc6 https://t.co/PCygEXKT8f
Dr. John Cush RheumNow ( View Tweet)
Subcutaneous Remsima, an infliximab biosimilar, has been FDA. Celltrion has rebranded this as Zymfentra, for maintenance therapy in adults with moderately to severely active Ulcerative colitis and Crohn's disease following (after giving IV infliximab) https://t.co/gvcssRuB92 https://t.co/dPYVi10KIA
Dr. John Cush RheumNow ( View Tweet)
Korean Insurance matched (1:10) claims cohort study (2010-2017) found bronchiectasis in 5.3% of 4845 systemic sclerosis pts vs 1.9% of non-SSc controls (24,225). SSc pts have a signif higher risk of bronchiectasis (adj HR 2.63), thus a minor feature of SSc https://t.co/7oOBkpw2DM https://t.co/683I0mMmQI
Dr. John Cush RheumNow ( View Tweet)
What Goes Wrong with the Immune System in #PMR?
Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease. Imaging studies have revealed that PMR should not be viewed as a mysterious source of pain and stiffness.
https://t.co/bQDcpM1ymQ https://t.co/B5anJolukY
Dr. John Cush RheumNow ( View Tweet)
#PMR TNR Pearls
Lessons learned from this months Tuesday Nite Rheumatology (TNR) sessions.
https://t.co/HiYcHL52hO https://t.co/z0xuYODLXV
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Bimekizumab for Plaque Psoriasis
UCB announced today that the FDA has approved bimekizumab-bkzx (Bimzelx)) for the treatment of moderate to severe plaque psoriasis in adults who needing systemic therapy or phototherapy.
https://t.co/BqeSAAxtQb https://t.co/LFjzkmAC5w
Dr. John Cush RheumNow ( View Tweet)
Using Methotrexate in #PMR
Where in other inflammatory rheumatic disorders, such as RA and PsA, early initiation of MTX is common practice, this is not the case in PMR. Treatment of PMR is still largely based on GC.
https://t.co/fW9BL3YWS5 https://t.co/bQwozOPUvJ
Dr. John Cush RheumNow ( View Tweet)
2023 EULAR Lupus Management Recommendations
EULAR has published updated recommendations for the management of systemic lupus erythematosus (SLE) based on new evidence and expert opinion - formulationg five overarching principles and 13 recommendations.
https://t.co/LainTFQBDg https://t.co/4b4h1fy6M3
Dr. John Cush RheumNow ( View Tweet)
JAKne? Systematic review &meta-analysis (25 studies, 10 839 pts), JAK inhibitor use was associated with an elevated odds of acne (OR 3-5 for UPA, TOFA, BARI, Deucra; but higher for abrocitinib (OR 13.5). Seen in Derm pts but hardly at all in Rheum pts https://t.co/En8HCqwqjO https://t.co/ak216wmlBA
Dr. John Cush RheumNow ( View Tweet)
